reports
Independent Research
- Independent Research
Chimeric Therapeutics Limited (ASX: CHM)
Full report available at Chimeric Therapeutics Limited (ASX: CHM) is a clinical stage cell therapy company that is seeking to develop novel cell therapies to potentially treat a range of cancers. The Company was listed in January 2021 and has a portfolio of autologous CAR-T candidates which it is seeking to develop and has recently expanded the portfolio with the option to licence an allogeneic CAR-NK platform.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.